Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023)

Novartis Ag (NVS) posted Liabilities from Discontinued Operations of 34000000.0 for Q2 2023, up 9.68% sequentially from 31000000.0 in Q4 2019.

Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023) Analysis & Trends

Novartis Ag (NVS) has 5 years of Liabilities from Discontinued Operations data on file, last reported at 34000000.0 in Q2 2023.

  • Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 34000000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 34000000.0 (changed N/A YoY) and the FY2019 annual result came in at 31000000.0, down 39.22% from the prior year.
  • Liabilities from Discontinued Operations grew to 34000000.0 in Q2 2023 per NVS's latest filing, from 31000000.0 in the prior quarter.
  • The five-year high for Liabilities from Discontinued Operations was 50000000.0 in Q2 2019, with the low at 24000000.0 in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Jun 30, 2023 34.00 Mn
Jun 30, 2023 34.00 Mn
Dec 31, 2019 31.00 Mn
Dec 31, 2019 31.00 Mn
Sep 30, 2019 24.00 Mn
Sep 30, 2019 24.00 Mn
Jun 30, 2019 50.00 Mn
Jun 30, 2019 50.00 Mn
Mar 31, 2019 41.00 Mn
Mar 31, 2019 41.00 Mn
Dec 31, 2018 51.00 Mn
Dec 31, 2018 51.00 Mn
Sep 30, 2018 76.00 Mn
Sep 30, 2018 76.00 Mn
Jun 30, 2015 222.00
Jun 30, 2015 222.00
Mar 31, 2015 225.00
Mar 31, 2015 225.00
Dec 31, 2014 2.42 Bn
Dec 31, 2014 2.42 Bn